HSKA 15.19 Heska Corp $HSKA Hit a 52 week high of

HSKA 15.19 Heska Corp $HSKA Hit a 52 week high of 15.27 Closing the day 11/06/14 at 15.19 +0.69 +4.76% With a day low of 14.35 and a total volume of 102,622.

HSKA Recent Posts: http://investorshangout.com/Heska-Corp-HSKA-54376/

HSKA Heska Corp Recent Headline News

Achillion Pharmaceuticals Slumps: ACHN Plunges 15.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:34AM CST
Achillion Pharmaceuticals (ACHN) fell nearly 16% in the last trading session amid huge volumes, reversing its recent trend, as the stock is now up nearly 3% in the past one month.
AGEN: 3.05 (+0.05), HSKA: 15.19 (+0.69), ACHN: 10.26 (+0.11), AMAG: 34.12 (+0.34)

Heska Announces Investor Day in New York City
PR Newswire - Tue Nov 04, 8:00AM CST
Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company" , a provider of advanced veterinary diagnostic and other specialty veterinary products, today announced the Company will conduct an Investor Day, from 9 a.m. to noon (EST) on Friday, November 14, 2014. The event will be at the Nasdaq MarketSite in Times Square, located at One Liberty Plaza, 165 Broadway, in New York City.
HSKA: 15.19 (+0.69)

Qiagen Q3 Earnings, Revenues in Line; Outlook Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 1:50PM CDT
Qiagen's (QGEN) strategic collaborations, test menu expansions and moderately balanced international expansion will likely drive growth over time.
BIIB: 323.47 (+3.92), HSKA: 15.19 (+0.69), ILMN: 189.87 (+3.50), QGEN: 23.68 (+0.15)

Can the Rally in Heska (HSKA) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:06AM CDT
Can the Rally in Heska (HSKA) Shares Continue?
HSKA: 15.19 (+0.69)

Heska Reports 24% Revenue Growth, $0.08 Per Share for the Third Quarter of 2014
PR Newswire - Wed Oct 29, 8:00AM CDT
Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company" , a provider of advanced veterinary diagnostic and other specialty veterinary products, today reported financial results for its third quarter ended September 30, 2014.
HSKA: 15.19 (+0.69)

Heska Signs Distribution Agreement with Henry Schein Animal Health
PR Newswire - Wed Oct 29, 7:45AM CDT
Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company" , a provider of advanced veterinary diagnostic and other specialty veterinary products, announced today a new distribution agreement with Henry Schein Animal Health, the largest companion animal health distribution company in the U.S. Henry Schein Animal Health will market and promote Heska's full line of hematology and chemistry instruments and affiliated consumables, effective immediately.
HSKA: 15.19 (+0.69), HSIC: 130.31 (+8.10)

Webcast Alert: Heska Announces Third Quarter 2014 Earnings Conference Call Webcast
PR Newswire - Tue Oct 28, 3:30PM CDT
Heska Corporation (Nasdaq: HSKA) announces the following Webcast:
HSKA: 15.19 (+0.69)

Repros Therapeutics (RPRX) Worth Watching: Stock Up 17% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 8:46AM CDT
Repros Therapeutics (RPRX) was a big mover last session, with shares surging almost 17% on the day.
CBM: 23.48 (+0.55), HSKA: 15.19 (+0.69), GILD: 106.94 (+0.89), RPRX: 6.45 (+0.03)

Cyclacel Pharmaceuticals (CYCC) in Focus: Stock Jumps 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 8:21AM CDT
Cyclacel Pharmaceuticals, Inc. (CYCC) was a big mover last session, as the company saw its shares rise by over 5% on the day.
HSKA: 15.19 (+0.69), CBM: 23.48 (+0.55), CYCC: 3.15 (-0.05), GILD: 106.94 (+0.89)

Myriad Genetics Poised on Strong myRisk, Overseas Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 2:20PM CDT
Currently, Myriad Genetics (MYGN) is financing 13 Phase III clinical trials with flagship product BracAnalysis CDx in six different indicated patient populations.
MYGN: 34.78 (+0.17), HSKA: 15.19 (+0.69), CBM: 23.48 (+0.55), GILD: 106.94 (+0.89)

Qiagen's Molecular Diagnostics, Global Market Show Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 1:50PM CDT
On Sep 25, we issued an updated research report on Qiagen N.V. (QGEN).
HSKA: 15.19 (+0.69), GILD: 106.94 (+0.89), ANTH: 1.86 (unch), QGEN: 23.68 (+0.15)

Rexahn Pharmaceuticals (RNN) Jumps: Stock Gains 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 8:25AM CDT
Rexahn Pharmaceuticals (RNN) was a big mover last session, as the company saw its shares rise over 10% on the day.
RNN: 0.70 (-0.02), HSKA: 15.19 (+0.69), CBM: 23.48 (+0.55), GILD: 106.94 (+0.89)

Dynavax (DVAX) Jumps: Stock Moves 6.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 8:46AM CDT
Dynavax (DVAX) was a big mover last session, with shares rising nearly 7% on the day.
DVAX: 1.59 (+0.04), HSKA: 15.19 (+0.69), GILD: 106.94 (+0.89), ILMN: 189.87 (+3.50)

Alder Biopharmaceuticals (ALDR) in Focus: Stock Up 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 7:44AM CDT
Alder Biopharmaceuticals Inc. (ALDR) was a big mover last session, as the company saw its shares rise over 5% on the day.
ALDR: 16.82 (-0.23), CBM: 23.48 (+0.55), HSKA: 15.19 (+0.69), ILMN: 189.87 (+3.50)

Is Illumina (ILMN) a Buy on Solid Q2, Strategic Road Map? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 2:30PM CDT
On Sep 16, 2014, we issued an updated research report on life sciences company Illumina Inc. (ILMN).
HSKA: 15.19 (+0.69), GILD: 106.94 (+0.89), AMGN: 160.35 (+1.41), ILMN: 189.87 (+3.50)

Dendreon (DNDN) in Focus: Stock Up 9.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 7:44AM CDT
Dendreon Corp. (DNDN) was a big mover last session, as the company saw its shares rise over 9% on the day
CBM: 23.48 (+0.55), HSKA: 15.19 (+0.69), DNDN: 0.83 (-0.10), ILMN: 189.87 (+3.50)

Cytokinetics (CYTK) Looks Strong: Stock Gains 17.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 7:44AM CDT
Cytokinetics (CYTK) as a big mover last session, as the company saw its shares surge over 17 % on the day
CYTK: 4.25 (+0.11), CBM: 23.48 (+0.55), HSKA: 15.19 (+0.69), ILMN: 189.87 (+3.50)

Synthetic Biologics (SYN) Looks Strong: Stock Gains 13.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 7:44AM CDT
Synthetic Biologics (SYN) was a big mover last session, as the company saw its shares gain nearly 14% on the day
SYN: 1.42 (-0.08), CBM: 23.48 (+0.55), HSKA: 15.19 (+0.69), ILMN: 189.87 (+3.50)

China Biologic Products, Inc. (CBPO) Rises: Stock Jumps 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 8:32AM CDT
China Biologic Products, Inc. (CBPO) was a big mover last session, as the company saw its shares rise more than 7% on the day.
CBPO: 68.98 (+5.71), HSKA: 15.19 (+0.69), CBM: 23.48 (+0.55), GILD: 106.94 (+0.89)